Literature DB >> 11402222

Mitochondrial toxicity and HIV therapy.

A J White1.   

Abstract

Nucleoside reverse transcriptase inhibitors (NRTIs) remain the cornerstone of highly active antiretroviral therapy (HAART) combination regimens. However, it has been known for some time that these agents have the potential to cause varied side effects, many of which are thought to be due to their effects on mitochondria. Mitochondria, the key energy generating organelles in the cell, are unique in having their own DNA, a double stranded circular genome of about 16 000 bases. There is a separate enzyme present inside the cell that replicates mitochondrial DNA, polymerase gamma. NRTIs can affect the function of this enzyme and this may lead to depletion of mitochondrial DNA or qualitative changes. The study of inherited mitochondrial diseases has led to further understanding of the consequences of mutations or depletion in mitochondrial DNA. Key among these is the realisation that there may be substantial heteroplasmy among mitochondria within a given cell, and among cells in a particular tissue. The unpredictable nature of mitochondrial segregation during cellular replication makes it difficult to predict the likelihood of dysfunction in a given tissue. In addition, there is a threshold effect for the expression of mitochondrial dysfunction, both at the mitochondrial and cellular level. Various clinical and in vitro studies have suggested that NRTIs are associated with mitochondrial dysfunction in different tissues, although the weight of evidence is limited in many cases. The heterogeneity in the tissues affected by the different drugs raises interesting questions, and possible explanations include differential distribution or activation of these agents. This article reviews the major recognised toxicities associated with NRTI therapy and evidence for mitochondrial dysfunction in these complications. Data were identified through searching of online databases including Medline and Current Contents for relevant articles, along with abstracts and posters from recent conferences in the HIV and mitochondrial fields.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11402222      PMCID: PMC1744319          DOI: 10.1136/sti.77.3.158

Source DB:  PubMed          Journal:  Sex Transm Infect        ISSN: 1368-4973            Impact factor:   3.519


  123 in total

1.  Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy.

Authors:  B Allaouchiche; F Duflo; L Cotte; L Mathon; D Chassard
Journal:  J Antimicrob Chemother       Date:  1999-07       Impact factor: 5.790

2.  Altered residual ATP content in rat brain cortex subcellular fractions following status epilepticus induced by lithium and pilocarpine.

Authors:  N Y Walton; A K Nagy; D M Treiman
Journal:  J Mol Neurosci       Date:  1998-12       Impact factor: 3.444

3.  Antiviral nucleoside toxicity in canine bone marrow progenitor cells and its relationship to drug permeation.

Authors:  T C Chan; G D Boon; L Shaffer; R Redmond
Journal:  Eur J Haematol       Date:  1992-08       Impact factor: 2.997

Review 4.  DNA polymerases versus HIV reverse transcriptase in AIDS therapy.

Authors:  Y C Cheng; W Y Gao; C H Chen; M Vazquez-Padua; M C Starnes
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

5.  Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis.

Authors:  J L Martin; C E Brown; N Matthews-Davis; J E Reardon
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

Authors:  A Carr; J Miller; M Law; D A Cooper
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

7.  Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease.

Authors:  D M Aboulafia; R Johnston
Journal:  AIDS Patient Care STDS       Date:  2000-01       Impact factor: 5.078

8.  Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion.

Authors:  P Chariot; I Drogou; I de Lacroix-Szmania; M C Eliezer-Vanerot; B Chazaud; A Lombès; A Schaeffer; E S Zafrani
Journal:  J Hepatol       Date:  1999-01       Impact factor: 25.083

9.  Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials.

Authors:  D H Henry; G N Beall; C A Benson; J Carey; L A Cone; L J Eron; M Fiala; M A Fischl; S J Gabin; M S Gottlieb
Journal:  Ann Intern Med       Date:  1992-11-01       Impact factor: 25.391

10.  Zidovudine-induced experimental myopathy: dual mechanism of mitochondrial damage.

Authors:  A Masini; C Scotti; A Calligaro; O Cazzalini; L A Stivala; L Bianchi; F Giovannini; D Ceccarelli; U Muscatello; A Tomasi; V Vannini
Journal:  J Neurol Sci       Date:  1999-07-01       Impact factor: 3.181

View more
  44 in total

1.  Evaluation of mitochondrial toxicity in Marmota himalayana treated with metacavir, a novel 2',3'-dideoxyguanosine prodrug for treatment of hepatitis B Virus.

Authors:  Pinghu Zhang; Luyong Zhang; Zhenzhou Jiang; Yating Xiong; Hongkui Chen; Yuanqing Tao; Maozhi Hu; Zhan Li
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

2.  In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

Authors:  Z Gu; B Allard; J M de Muys; J Lippens; R F Rando; N Nguyen-Ba; C Ren; P McKenna; D L Taylor; R C Bethell
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

3.  Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)--2',3'-dideoxycytidine (ddC): relevance to HIV-dementia.

Authors:  Wycliffe O Opii; Rukhsana Sultana; Hafiz Mohmmad Abdul; Mubeen Ahmad Ansari; Avindra Nath; D Allan Butterfield
Journal:  Exp Neurol       Date:  2006-10-25       Impact factor: 5.330

4.  Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.

Authors:  Joy Y Feng; Guofeng Cheng; Jason Perry; Ona Barauskas; Yili Xu; Martijn Fenaux; Stacey Eng; Neeraj Tirunagari; Betty Peng; Mei Yu; Yang Tian; Yu-Jen Lee; George Stepan; Leanna L Lagpacan; Debi Jin; Magdeleine Hung; Karin S Ku; Bin Han; Kathryn Kitrinos; Michel Perron; Gabriel Birkus; Kelly A Wong; Weidong Zhong; Choung U Kim; Anne Carey; Aesop Cho; Adrian S Ray
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

5.  Protease inhibitor related type III hyperlipoproteinaemia is common and not associated with apolipoprotein-E E2/E2 phenotype.

Authors:  M Shahmanesh; H Jaleel; Y DeSilva; J D Ross; M Caslake; R Cramb
Journal:  Sex Transm Infect       Date:  2001-08       Impact factor: 3.519

Review 6.  Neuromuscular complications in HIV.

Authors:  Susama Verma; Elena Micsa; Lydia Estanislao; David Simpson
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

7.  Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs.

Authors:  Kaleb C Lund; LaRae L Peterson; Kendall B Wallace
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

Review 8.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

Review 9.  Drug-Induced Mitochondrial Toxicity.

Authors:  Iain P Hargreaves; Mesfer Al Shahrani; Luke Wainwright; Simon J R Heales
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

10.  The Relationship Between HIV Infection and Cardiovascular Disease.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.